Cancer-data Company by Erick Lefkofsky, Tempus will get a boost worth $70 million form Revolution Growth and New Enterprise Associates. The two venture funds which are based in Washington, DC led a new financing round which has brought the sum of outside investments in Tempus to approximately $130 million. Eric Lefkofsky established Tempus two years ago where he served as the co-founder of the company. He also served as the Chief Executive Officer of Groupon. Since its inception, Tempus has managed to offer their services to almost 200 individuals including a close family member of Eric Lefkofsky and learn more about Eric.
Tempus has been described as a Big Data play when it comes to oncology. Many hospitals normally send their patients to Tempus to get genetic analysis and sequencing. The software platform of Tempus uses data so as to offer doctors information regarding treatment options for each patient, indicating how other people with the same genetics profiles have managed to respond to specific therapies. One of the biggest challenges that Tempus has faced is getting sufficient partners to create a critical data mass. According to Eric Lefkofsky, it has been a great worry for him if the top academic medical cancer centers will be able to contribute data and Eric on Facebook.
Eric Lefkofsky says that the additional funds will assist Tempus in building out the database it collects from top academic medical cancer centers. Since its inception, Tempus has managed to sign many top hospitals such as University of Chicago Medicine, Northwestern University’s Lurie Cancer Center, University of Pennsylvania’s Abramson Cancer center, University of Michigan, Mayo Clinic, Cleveland Clinic and Duke University School of Medicine. After being in the business for two years, Eric Lefkofsky stated that the company is ahead of the target that they had set initially and Eric’s lacrosse camp.
An established entrepreneur, Eric Lefkofsky is the co-founder of Tempus. Under his leadership, the company has managed to experience lots of success and growth. Eric is responsible for ensuring that the strategic goals of the company are achieved. He attributes the success that he has had with Tempus and throughout his career to hard work, passion, commitment and discipline and read full article.
More visit: http://www.bloomberg.com/research/stocks/people/person.asp?personId=166953&privcapId=82311805
Jim Tananbaum, the CEO of Foresite Capital, has demonstrated his superiority in the business world by appearing in the 2017 Forbes’ Midas List of Top 100 Tech Investors. The visionary leader was ranked position 52. This is his third consecutive year to be recognized by the prestigious Forbes Magazine. This achievement reflects his continuous dedication to success at Foresite Capital, a healthcare investment company. The Forbes’s Midas List honors venture capitalists who exhibit excellent performance in top tech companies of tomorrow and those who create unique value for their investors. Forbes partners with TrueBridge Capital Partners to collect data from various public sources before calculating and determining the ideal ranks of the venture capitalist’s investment. The investments include the size of private valuation, deal value and other major metrics against their peers. You can visit Ideamensch to know more.
Dr. Jim Tananbaum has rendered his services in the healthcare industry for many years. He primarily focuses on entrepreneurship and investment. Jim is the founder of Foresite Capital, where he also serves as the managing director. Here, Jim Tananbaum builds franchise healthcare companies through strategic, financial and operational opportunities. He oversees the company’s investment strategy and organizational structure. Foresite Capital invests in biotechnology, diagnostics, genomics, medical devices and healthcare services. His involvement in the business has seen him found and fund various companies. In 2001, Jim Tananbaum co-founded Prospect Venture Partners (PVP) where he served as the managing director for 9 years. PVP, a $1 billion healthcare venture capital group, specialized in series A financings.
In addition, Dr. Tananbaum co-founded Theravance (THRX), where he served as the CEO for three years. Previously, Jim was a Partner at Sierra Ventures where he led investments in Healtheon, Amerigroup, Novamed and Careselect. Tananbaum is also the co-founder and CEO of Geltex Pharmaceuticals, where he helped to create two non-systematic drugs, Renzela and Cholestagel. The company was later sold at $1.6 billion. Presently, he serves as the president of the Advisory Board of Yale University and Advisor at Harvard MIT HST Program. Notably, the doctor is an alumnus of the celebrated Harvard Medical School where he graduated with his MD and a master’s of science degree. He is highly skilled in deal sourcing, mergers, IPO, private equity, due diligence and corporate development. Check out Forbes for more details.
Check out his website officialjimtananbaum.com
Click here: http://www.fiercebiotech.com/venture-capital/foresite-capital-reloads-a-450m-biotech-venture-fund